These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 9733353

  • 21. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR, Litvack F, Eigler NL, Nakamura M, Ivey PA, Forrester JS, Shah PK, Jordan RE, Kaul S.
    Circulation; 1997 Feb 18; 95(4):1015-21. PubMed ID: 9054765
    [Abstract] [Full Text] [Related]

  • 22. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
    Di Pasquale P, Sarullo FM, Cannizzaro S, Vitrano MG, Giubilato A, Scalzo S, Giambanco F, Paterna S.
    Ital Heart J; 2001 Oct 18; 2(10):751-6. PubMed ID: 11721719
    [Abstract] [Full Text] [Related]

  • 23. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI, Hokamura K, Kondo K, Ikeda Y, Suzuki Y, Umemura K.
    Eur J Pharmacol; 2001 Apr 13; 417(3):217-22. PubMed ID: 11334853
    [Abstract] [Full Text] [Related]

  • 24. Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.
    Rebello SS, Kasiewski CJ, Bentley RG, Morgan SR, Chu V, Bostwick JS, Klein SI, Perrone MH, Leadley RJ.
    Thromb Res; 2001 May 01; 102(3):261-71. PubMed ID: 11369420
    [Abstract] [Full Text] [Related]

  • 25. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors.
    Kleiman NS.
    Am Heart J; 1999 Oct 01; 138(4 Pt 2):263-75. PubMed ID: 10502232
    [Abstract] [Full Text] [Related]

  • 26. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
    Hoffmann P, Bernat A, Savi P, Herbert JM.
    J Cardiovasc Pharmacol; 1997 Sep 01; 30(3):360-6. PubMed ID: 9300321
    [Abstract] [Full Text] [Related]

  • 27. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE.
    Am Heart J; 2000 Apr 01; 139(4):696-703. PubMed ID: 10740154
    [Abstract] [Full Text] [Related]

  • 28. The effects of two synthetic glycoprotein IIb/IIIa antagonists, Ro 43-8857 and L-700,462, on platelet aggregation and bleeding in guinea-pigs and dogs: evidence that Ro 43-8857 is orally active.
    Cook NS, Bruttger O, Pally C, Hagenbach A.
    Thromb Haemost; 1993 Nov 15; 70(5):838-47. PubMed ID: 8128443
    [Abstract] [Full Text] [Related]

  • 29. Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in humans.
    Graff J, Klinkhardt U, Westrup D, Kirchmaier CM, Breddin HK, Harder S.
    Br J Clin Pharmacol; 2003 Sep 15; 56(3):321-6. PubMed ID: 12919181
    [Abstract] [Full Text] [Related]

  • 30. Antiplatelet and antithrombotic effects of orbofiban, a new orally active GPIIb/IIIa antagonist, in guinea pigs.
    Ogawa T, Sugidachi A, Naganuma H, Asai F.
    Thromb Res; 2000 Mar 01; 97(5):307-15. PubMed ID: 10709906
    [Abstract] [Full Text] [Related]

  • 31. Ex vivo--in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A.
    Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S.
    Clin Pharmacol Ther; 2000 Mar 01; 67(3):305-13. PubMed ID: 10741635
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Oral glycoprotein IIb/IIIa antagonists: new insights from the SYMPHONY trial.
    McGuire DK, Newby LK.
    J Thromb Thrombolysis; 2000 Oct 01; 10(2):111-9. PubMed ID: 11005932
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
    Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G.
    Circulation; 1996 Nov 01; 94(9):2083-9. PubMed ID: 8901655
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Antithrombotic activity of Z4A5, a new platelet glycoprotein IIb/IIIa receptor antagonist evaluated in a rabbit arteriovenous shunt thrombosis model.
    Jing BB, Li YX, Zhang H, Ren ST, Wang M, Li YP, Zang WJ, Wang B.
    Thromb Res; 2011 Nov 01; 128(5):463-9. PubMed ID: 21924458
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.